New drug cocktail aims to Re-Sensitize Immunotherapy-Resistant lung cancer

NCT ID NCT07412262

Not yet recruiting Disease control Sponsor: Guangdong Association of Clinical Trials Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether combining chidamide (a pill) with ivonescimab (an infusion) can help people with advanced non-small cell lung cancer whose tumors have stopped responding to immunotherapy and have a specific protein marker called YAP. The study will enroll 32 adults and measure how long the cancer stays under control. It is not yet recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chidamide (tucidinostat) and ivonescimab (AK112)
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced lung cancer whose disease has stopped responding to immunotherapy.
What could go wrong: This is a small, early-phase trial with only 32 participants and no comparison group. The combination may not improve outcomes and could cause side effects like fatigue, low blood counts, or immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China

Guangzhou, Guangdong, 510080, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.